Depression is exhausting. Depression that does not respond to treatment is something else entirely. When you have taken the medication, gone to the appointments, made the lifestyle changes everyone recommends, and still feel the weight of depression pressing down on you, the question stops being “what should I try?” and becomes “is there anything left to try?”
The answer, for most people, is yes. But the path forward looks different than the path that brought you here, and it requires a psychiatrist who specializes in cases that have not responded to standard care. Treatment-resistant depression has well-established next steps, and at the practice of Dr. Raul J. Rodriguez in Delray Beach, those next steps are exactly what we focus on every day.
Treatment-resistant depression, often abbreviated as TRD, has a specific clinical definition. It refers to major depressive disorder that has not responded adequately to at least two different antidepressant medications, taken at therapeutic doses, for an appropriate length of time. The medications must come from different classes or have meaningfully different mechanisms, and the trials must have been long enough for the medication to actually have a chance to work, typically six to eight weeks at the right dose.
That definition matters because it rules out some of the more common reasons a depression treatment might appear to fail. A medication stopped after two weeks was never given a fair trial. A dose that was never titrated to a therapeutic level cannot be called a failed trial either. Part of what we do in evaluating a new patient is reviewing the full treatment history to understand whether you are truly facing treatment-resistant depression or whether the standard treatments simply have not been delivered in a way that gave them a real opportunity to work.
When the diagnosis of treatment-resistant depression is confirmed, the conversation shifts. Continuing to cycle through additional first-line antidepressants becomes less productive. The treatments that move the needle for treatment-resistant depression are different from the ones that work for typical major depression, and they are exactly the treatments our practice was built around.
The first thing that often changes with treatment-resistant depression is the medication strategy itself. Standard prescribing relies on a relatively narrow set of first-line antidepressants. Advanced psychopharmacology, which is one of the core specialties of Dr. Rodriguez’s psychiatric practice, draws on a much broader toolkit.
Augmentation is one common approach. Instead of replacing the medication you are on, we add a second medication that works through a different mechanism to enhance the antidepressant effect. This might involve a mood stabilizer, an atypical antipsychotic at low dose, thyroid hormone, or another agent whose role in depression treatment is well-documented but underused outside of specialty practices.
Combination therapy goes a step further by pairing two antidepressants with complementary mechanisms. This is not something to attempt without specialized psychiatric expertise, because medication interactions and side effect profiles become more complex. But in the right hands, combination strategies can produce meaningful improvement in patients who responded only partially to monotherapy.
Switching to a less commonly used medication class is another option. Tricyclic antidepressants, MAOIs, and other older medications have fallen out of routine first-line use, but they remain genuinely effective for patients whose depression has not responded to newer agents. The reason they are not prescribed more often is that they require closer monitoring and a psychiatrist comfortable managing them. That experience is part of what Dr. Rodriguez brings to treatment-resistant cases.
When medication strategies have been exhausted or are producing diminishing returns, the next category of treatment moves beyond pharmacology. Deep transcranial magnetic stimulation, known as deep TMS or dTMS, is one of the most effective options available for treatment-resistant depression.
TMS works by delivering focused magnetic pulses to specific areas of the brain involved in mood regulation. These pulses stimulate neuronal activity in regions that are underactive in depression, encouraging the brain to restore healthier patterns of function. It is FDA-cleared for the treatment of major depressive disorder in patients who have not responded adequately to antidepressant medication, which makes it a particularly well-fitting option for treatment-resistant cases.
What makes deep TMS distinct from earlier TMS systems is the depth and breadth of stimulation it provides. The technology reaches deeper brain structures with broader coverage, which has translated into improved outcomes in clinical studies. For patients who have spent years trying medications without finding relief, the experience of TMS treatment is often surprising. There is no anesthesia. There is no medication interaction to manage. You sit in a chair, the device delivers stimulation, and you go back to your day.
Treatment courses typically span several weeks of sessions, with most patients beginning to notice changes in mood, sleep, or energy before the course is complete. Because TMS works through an entirely different mechanism than medication, it can be effective for patients whose depression has not budged with even multiple medication trials.
For some patients with treatment-resistant depression, the urgency of the situation matters as much as the eventual outcome. Severe depression that includes suicidal thoughts, complete loss of function, or rapid deterioration cannot always wait for a six-week medication trial or a multi-week TMS course. This is where IV ketamine infusion therapy plays a distinct and important role.
Ketamine works on the glutamate system, a different neurotransmitter pathway than the serotonin, norepinephrine, and dopamine systems targeted by traditional antidepressants. This different mechanism is why ketamine can produce meaningful improvement in depression that has not responded to standard medications. It is also why the timeline is so different. Many patients experience a noticeable reduction in depressive symptoms within hours to days of an infusion, rather than the weeks required for traditional antidepressants to take effect.
In our practice, IV ketamine infusions are administered in a controlled clinical setting with appropriate monitoring throughout the treatment. The infusions are not a one-time event. A standard protocol typically involves a series of infusions over a defined period, followed by maintenance infusions tailored to the individual response. Ketamine is not a replacement for ongoing psychiatric care, and we integrate it into a broader treatment plan that addresses the longer-term management of your depression.
For patients in acute distress, the speed of ketamine’s effect can be the difference between a hospitalization and an outpatient turnaround. For patients with chronic, grinding, treatment-resistant depression, it can be the intervention that finally creates room for other treatments to take hold.
Treatment-resistant depression rarely responds to a single intervention in isolation. The patients who do best are typically those whose treatment plan combines biological interventions with structured therapeutic work, and our practice integrates several therapy modalities into the broader treatment approach.
Dialectical Behavior Therapy is one of the most effective therapeutic frameworks for patients whose depression includes intense emotional dysregulation, difficulty tolerating distress, or patterns of self-defeating behavior that perpetuate the depression itself. DBT provides concrete skills for managing emotions, navigating relationships, and tolerating the kinds of moments that have historically derailed your progress. For patients with treatment-resistant depression, those skills become tools that support the gains made through medication and procedural treatments.
Individual therapy gives you a private space to work through the specific circumstances and patterns that have shaped your depression. Treatment-resistant depression often has psychological dimensions that medication alone cannot address: trauma, grief, chronic relationship stress, or longstanding cognitive patterns that reinforce the illness. Individual therapy with a clinician who understands the complexity of treatment-resistant cases addresses those dimensions directly.
Group therapy adds something that individual work cannot provide on its own. The experience of speaking with others who are working through similar struggles, learning from their progress, and contributing to theirs is a meaningful part of recovery for many patients. The isolation that depression imposes is something group therapy actively works to dismantle.
What sets treatment-resistant depression care apart is not any single tool but the thoughtful combination of tools matched to your specific presentation. A patient whose depression includes prominent anxiety might benefit from a different combination than one whose depression is primarily anergic. A patient with co-occurring substance use needs a treatment plan that addresses both conditions in coordination. A patient who has tried many medications without response might be a strong candidate for TMS as a primary intervention, while another patient in acute distress might begin with ketamine and build the longer-term plan from there.
This is the kind of evaluation Dr. Rodriguez conducts with every new patient. The treatment history, the current symptoms, the lifestyle factors, the co-occurring conditions, and your own goals for treatment all inform the recommendation. Treatment-resistant depression is not a one-size-fits-all category, and the treatment plan should not be either.
For patients who cannot easily make it to our Delray Beach office for every appointment, psychiatric telemedicine makes ongoing medication management and supportive psychiatric care accessible from anywhere in Florida. The treatments that require in-person care, like TMS and IV ketamine, are scheduled in office, while the rest of the care can be coordinated remotely as your schedule and circumstances require.
The starting point for treatment-resistant depression is a thorough evaluation. We review your complete treatment history, including every medication you have tried, the doses, the durations, and the reasons each was discontinued. We assess current symptoms, co-occurring conditions, and any medical factors that might be contributing to or complicating the depression. We talk about what your life looks like now and what you want it to look like.
From there, we discuss the treatment options that fit your case and walk you through what each one involves. There is no pressure to commit on day one. Treatment-resistant depression is a serious diagnosis, and the right treatment plan is worth taking the time to build carefully.
If you have been struggling with depression that has not responded to standard treatment, you do not have to keep cycling through the same approaches that have not worked. There are real options, and they are exactly the options our practice is built around.
Dr. Raul J. Rodriguez has spent his career working with patients whose depression has not responded to standard care. The combination of advanced psychopharmacology, deep TMS, IV ketamine infusions, and integrated therapy that our practice offers gives patients with treatment-resistant depression a set of options that few practices can match.
To schedule a consultation and discuss our approach for your case, contact our office or call 888-551-6281. You can also learn more about Dr. Rodriguez and our practice to get a fuller picture of who we are and how we work. If your depression has not responded to what you have tried so far, we would welcome the opportunity to talk with you about what might come next.
